Foetal loss after chorionic villus sampling and amniocentesis in twin pregnancies: A multicentre retrospective cohort study

Kate Navaratnam1,2 | Delima Khairudin1 | Robyn Chilton2 | Andrew Sharp1,2 | George Attilakos3 | Daniel Stott3 | Sophie Relph3 | Rebecca Spencer4 | Dominique A. Badr5 | Andrew Carlin5 | Jacques Jani5 | Mark D. Kilby6,7 | Mercedes Sebghati8 | Asma Khalil1,8 | Zarko Alfirevic1,2

1Fetal Medicine Unit, Liverpool Women’s Hospital, Liverpool, UK
2Harris-Wellbeing Research Centre, University of Liverpool, Liverpool, UK
3Fetal Medicine Unit, University College London Hospital NHS Foundation Trust and Institute for Women’s Health, University College London, London, UK
4University of Leeds and Fetal Medicine Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
5Department of Obstetrics and Gynecology, University Hospital Brugmann, Université Libre de Bruxelles, Brussels, Belgium
6Institute of Metabolism & Systems Research, College of Medical & Dental Sciences, University of Birmingham, Birmingham, UK
7Fetal Medicine Centre, Birmingham Women’s and Children’s Foundation Trust, Birmingham, UK
8Fetal Medicine Unit, St George’s Hospital, St George’s University of London, London, UK

Correspondence
Kate Navaratnam, Harris-Wellbeing Research Centre, University of Liverpool, Liverpool, UK. Email: kate.navaratnam@liverpool.ac.uk

Abstract

Objective: We aimed to determine foetal losses for DCDA and MCDA twins following transabdominal CVS or amniocentesis performed <22+0 weeks.

Methods: Retrospective cohort study conducted in the UK and Belgium 01/01/00–01/06/20. Cases with unknown chorionicity, monochorionic complications or complex procedures were excluded. Uncomplicated DCDA and MCDA twins without invasive procedures were identified as controls. We reported foetal losses <24+0 weeks and losses of genetically and structurally normal foetuses.

Results: Outcomes were compared for DCDA foetuses; 258 after CVS with 3406 controls, 406 after amniocentesis with 3390 controls plus MCDA foetuses, 98 after CVS with 1124 controls, and 160 after amniocentesis with 1122 controls. There were more losses <24+0 weeks with both procedures in DCDA (CVS RR 5.54 95% CI 3.38–9.08, amniocentesis RR 2.36 95% CI 1.22–4.56) and MCDA twins (CVS RR 5.14 95% CI 2.51–10.54, amniocentesis RR 7.01 95% CI 3.86–12.74). Losses of normal foetuses were comparable to controls (DCDA CVS RR 0.39 95% CI 0.05–2.83, DCDA amniocentesis RR 1.16 95% CI 0.42–3.22, MCDA CVS RR 2.3 95% CI 0.71–7.56, and MCDA amniocentesis RR 1.93 95% CI 0.59–6.38).

Conclusions: This study indicates increased foetal losses for DCDA and MCDA twins following CVS and amniocentesis with uncertain risk to normal foetuses.

Key points

What’s already known about this topic?

- Monochorionic twins are at a higher baseline risk of foetal loss, but outcome data for these pregnancies following CVS and amniocentesis are limited.
- Procedure-related losses following CVS and amniocentesis in twins overall may be lower than previously reported.
1 | INTRODUCTION

Despite advances in non-invasive testing, chorionic villus sampling (CVS) and amniocentesis are the prenatal tests of choice for diagnosing chromosomal and genetic abnormalities. Assessment in a randomised controlled trial (RCT) is the gold standard to estimate a procedure-related risk. However, it is unlikely that appropriately powered, high-quality randomised controlled trials, evaluating comparative effects of CVS and amniocentesis would be feasible or acceptable to patient groups.

A recent meta-analysis reported a weighted pooled procedure-related risk of miscarriage for singletons of 0.35% for both CVS and amniocentesis.1 Accepting the limitations of observational data and relative imprecision of the estimated risks, recent RCOG guidance concluded that procedure-related risk of miscarriage for singleton pregnancy is likely to be less than 0.5%.2,3 Evidence quantifying procedure-related risks in multiple pregnancies is significantly more limited. Observational studies published in the last 2 decades suggest that the procedure-related risk of miscarriage in twins may be lower than previous estimates.4 A systematic review published in 2020 included 2713 amniocenteses procedures and 349 CVS in multiple pregnancies. The results indicated no significant difference in foetal loss before 24 weeks gestation and within 4 weeks of procedure, compared to those not undergoing an invasive procedure. These findings are further supported by a recent large multicentre retrospective cohort study that used logistic regression. The authors found no significant contribution of CVS to the risk of post-procedure miscarriage. Interestingly, when the same dataset was analysed using propensity scoring, there was a 3.5% higher absolute risk of foetal loss following CVS for women at a low baseline risk.5,6 Therefore, more evidence is needed to establish a robust evidence base and clarify inconsistent study findings.

Attempts to quantify procedure-related risks in multiple pregnancies are challenging. Published case series tend to be small with variation in definitions of procedure-related foetal loss.4 Monochorionicity, with shared vascular connections, confers additional complexity.7 Increased baseline risks, technical challenges, and post-procedure losses may be attributable to the monochorionicity rather than the procedure itself and yet this information is often unavailable or inadequately reported.

What does this study add?

- Spontaneous losses of twins prior to 24 weeks are increased after CVS and amniocentesis for both DCDA and MCDA pregnancies compared to controls.
- Losses of structurally and genetically normal twins appear comparable to control groups. However, due to low numbers of adverse outcomes in our cohort and other published analyses, further evidence is required.
- Maternal counselling should highlight different baseline risks between MCDA and DCDA twins and the contribution of maternal and pregnancy factors to outcomes for complex twin pregnancies.

2 | METHODS

This retrospective, multicentre cohort study included women with DCDA and MCDA twin pregnancies managed between 01/01/00 and 01/06/20 in six tertiary foetal medicine centres in the UK and Belgium, namely Birmingham Women’s and Children’s Foundation NHS Trust (BWH), Leeds Teaching Hospitals NHS Trust, Liverpool Women’s Hospital NHS Foundation Trust (LWH), St George’s Hospital, University College London Hospital and University Hospital Brugmann (UHJ), Brussels.

Routinely collected clinical data were sought and therefore ethical approval was not required, according to the Health Research Authority decision tool.8 Audit approval was obtained in each centre. All women were identified via electronic searches of local databases and medical records.

The control groups comprised women managed and delivering in LWH or UHB between 01/01/09 and 01/06/20 with two viable foetuses on scan between 11+0 and 14+0 weeks. These two centres were chosen for representative comparator groups for the study population overall. Both centres have comprehensive electronic records covering the chosen time period to allow identification of uncomplicated twin pregnancies.

The most appropriate control groups would comprise twins that had an indication for testing but declined prenatal diagnosis. However, as sufficiently large numbers would not be identifiable, we chose to compare with uncomplicated twins that had not undergone invasive diagnostic or therapeutic procedures. Pregnancies where chorionicity could not be determined or unobtainable outcomes were excluded. MCMA pregnancies, those with TRAP,
TTTS, or discordant structural or genetic abnormalities were excluded from control groups. Pregnancies affected by foetal loss between 11+0 and 15+0 weeks were excluded from the amniocentesis control group.

Women who had undergone CVS (11+0–22+0 weeks) or amniocentesis (15+0–22+0 weeks) in six centres between 01/01/00 and 01/06/20 were considered as the study group. Exclusion criteria included pregnancies where chorionicity could not be determined or with unobtainable outcomes. MCMA pregnancies, those with TRAP, and TTTS were excluded. We also excluded pregnancies when more than two attempts were required to obtain a sample, when procedures were performed alongside embryo reduction or when selective foetocide was performed within the reporting period (<24+0 weeks).

Twin chorionicity and amnionicity were determined by ultrasound scan in the first trimester as per evidence-based guidance.9,10 CVS and amniocentesis were carried out by foetal medicine specialists, using continuous ultrasound guidance and aseptic technique. 17–21G needles were used for CVS, 20–22G for amniocentesis. All CVS procedures were performed transabdominally and intramniotic dye infusion was not used for amniocentesis. Foetal well-being was assessed upon procedure completion.

For controls, CVS, and amniocentesis groups, we chose to assess losses at 11+0 weeks as, below this threshold, twin foetuses are unlikely to be viable. For controls, CVS, and amniocentesis groups, we reported overall foetal losses <24+0 weeks, including deaths of both foetuses and single foetal deaths and any reported deaths of structurally and genetically normal foetuses <24+0 weeks. For CVS and amniocentesis groups, we also reported overall foetal losses <24+0 weeks within 15 days of procedure, including death of both foetuses and single foetal deaths. We also reported any deaths of structurally and genetically normal foetuses within 2 weeks (<15 days) of the procedure as more likely to be related to the procedure.

Maternal demographic data were identified including indication for testing. Technical details of procedures and their complications were identified, including sampling from one or both twins, use of the same or separate needle (single puncture or separate punctures), bloodstaining of sample, maternal cell contamination, and failure to obtain a result. Anatomical findings, genetic results, and outcomes for both twins at 24+0 weeks gestation (number of foetuses alive) were extracted. For tertiary referrals, pregnancy outcome data were sought from referring hospitals via standard email request and followed up by telephone.

Statistical analyses were undertaken using SPSS version 27 (IBM Corp. Released 2020; IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp). Demographic and pregnancy data were reported per pregnancy; outcomes were reported per foetus. Relative risk (RR) with 95% confidence intervals (CI) was calculated for all outcomes following CVS and amniocentesis in monochorionic and dichorionic twins versus controls. Computational issues may occur when no events are observed in one or both groups analysed. Where no events occurred, a recognised zero cell correction was applied by adding 0.5 to affected cells prior to the analysis.11

Forest plots to compare our data to those recently published were generated in Revman 5.4 (The Cochrane Collaboration, available at revman.cochrane.org). Risk ratios with random effects were calculated for CVS and amniocentesis in DCDA and MCDA twins, respectively. Where judged appropriate, data were pooled.2

3 RESULTS

Changes in patient record systems in BWH and UHB meant that data for women who had invasive procedures could only be obtained between 01/01/06 and 30/09/19 in BWH and between 01/01/09 and 01/06/20 in UHB. In total, 899 women with twin pregnancies had CVS or amniocentesis during the study period. After exclusions, 129 women with DCDA twins had CVS and 203 had an amniocentesis. After exclusions, 49 women with MCDA twins had CVS and 80 had amniocentesis (Figure 1).

There were 2284 twin pregnancies that had not undergone invasive procedures. Seven DCDA and 12 MCDA cases were excluded, leaving 1703 DCDA pregnancies (3406 foetuses) and 562 MCDA pregnancies (1124 foetuses) as the control group for CVS. Eight DCDA and one MCDA cases affected by foetal losses between 11+0 and 15+0 were excluded, leaving 1695 pregnancies (3390 foetuses) and 561 pregnancies (1122 foetuses) as the control group for amniocentesis.

The median maternal age for DCDA controls was 32 years (IQR 28–36), whereas it was 35 years (IQR 31–39) for those who had prenatal diagnosis. The median age of MCDA controls was 30 years (interquartile range, IQR 26–34), whereas it was 34 years (IQR 29–38) for those who had prenatal diagnosis. Indications for prenatal diagnosis are shown in Table 1.

4 DICHORIONIC DIAMNIOTIC TWINS (DCDA)

In the CVS control group, 1.5% (50/3406) of foetuses died before 24+0 weeks, comprising 17 twin pair deaths (1%) and 16 single foetal deaths (0.5%). In the amniocentesis control group, 1.2% (39/3390) of foetuses died before 24+0 weeks, comprising 0.8% (28/3390) as twin pairs and 0.3% (11/3390) single foetal deaths (Table 2a).

4.1 CVS

In 62.3% (81/129) DCDA CVS, both placentas were sampled, and in 27.2% (22/81), separate needle insertions were used. All samples were obtained at the first attempt.

Following CVS in DCDA twin pregnancies, there was a significant increase in total foetal deaths prior to 24+0 weeks (8.1%, 21/258, RR 5.54 95% CI 3.38–9.08), mostly due to single foetal deaths (6.6%, 17/258, RR 14.03 95% CI 7.17–27.43) (Table 2a).

Eleven foetuses died within 2 weeks of CVS, including two twin pairs, and seven foetuses survived by their co-twin (Table S1a).
There were no losses of structurally and genetically normal foetuses in the CVS group, which were comparable to losses that occurred in controls (1.5%, 50/3406, RR 0.39 95% CI 0.05–2.83) (Table 2a).

### 4.2 Amniocentesis

In 80.3% (163/203) DCDA amniocentesis, both amniotic sacs were sampled, and in 87.7% (143/163), separate needle insertions were used. Three cases required a second attempt to obtain the sample. Following amniocentesis in DCDA twins, there was also a significant increase in total foetal deaths prior to 24+0 weeks (2.7%, 11/406, RR 1.85 95% CI 0.97–3.52), also largely composed of single foetal deaths (1.7%, 7/406, RR 3.67 95% CI 1.52–8.87) (Table 2a).

Three foetuses died within 2 weeks of amniocentesis, including one twin pair and one foetus survived by their co-twin (Table 51b). Overall, there were two losses of pairs of genetically and structurally normal twins, including the twin pair that died within 2 weeks of amniocentesis (Table 51b). Similar losses of normal foetuses were observed in the amniocentesis group and control group (1.3% 4/300 vs. 1.2% 39/3390 RR 1.16 95% CI 0.42–3.22) (Table 2a).
In the CVS control group, 2.0% (22/1124) of foetuses died before 24+0 weeks, comprising 0.5% (6/1124) as twin pairs and 1.4% (16/1124) single foetal deaths. In the amniocentesis control group, 1.8% (20/1122) of foetuses died before 24+0, comprising 0.4% (4/1122) within twin pairs and 1.4% (16/1122) single foetal deaths (Table 2b).

5.1 CVS

In 34.7% (17/49) MCDA CVS, both placentas were sampled, and in 17.6% (3/17), separate needle insertions were used. One case required a second attempt to obtain the sample.

Following CVS in MCDA twin pregnancies, there was a significant increase in total foetal deaths prior to 24+0 weeks (10.2%, 10/98, RR 5.14 2.51–10.54), with a significant increase in deaths of twin pairs (6.1%, 6/98, 3.77–34.89) (Table 2b).

| Outcome                              | Controls n = 3406 | CVS n = 258 RR (95% CI) | Controls n = 3390 | Amniocentesis n = 406 RR (95% CI) |
|--------------------------------------|-------------------|-------------------------|-------------------|----------------------------------|
| Total twins alive at 24+0 weeks       | 3356 (98.5%)      | 237 (91.9%) 0.93 (0.90–0.97) | 3351 (98.8%) 0.98 (0.97–1.00) |
| Both twins in pair alive at 24+0 weeks | 3340 (98.1%)      | 220 (85.3%) 0.88 (0.83–0.92) | 3340 (98.5%) 0.97 (0.95–0.99) |
| Total twins lost <24+0 weeks          | 50 (1.5%)         | 21 (8.1%) 5.54 (3.38–9.08) | 39 (1.2%) 2.36 (1.22–4.56)  |
| Single twin demise                    | 16 (0.5%)         | 17 (6.6%) 14.03 (7.17–27.43) | 11 (0.3%) 7.31 (2.07–13.63) |
| Both twins demised                    | 34 (1.0%)         | 4 (1.6%) 1.55 (0.56–4.34) | 28 (0.8%) 1.19 (0.42–3.38) |
| Losses of normal twins*               | 50 (1.5%)         | 0 (0%) 0.39 (0.05–2.83) | 39 (1.2%) 1.16 (0.42–3.22) |

| Outcome                              | Controls n = 1124 | CVS n = 98 RR (95% CI) | Controls n = 1122 | Amniocentesis n = 160 RR (95% CI) |
|--------------------------------------|-------------------|-------------------------|-------------------|----------------------------------|
| Total twins alive at 24+0 weeks       | 1102 (98.0%)      | 86 (78.8%) 0.90 (0.83–0.96) | 1102 (98.2%) 0.89 (0.84–0.95) |
| Both twins in pair alive at 24+0 weeks | 1086 (96.6%)      | 84 (85.7%) 0.89 (0.82–0.96) | 1086 (96.8%) 0.88 (0.82–0.94) |
| Total twins lost <24+0 weeks          | 22 (2.0%)         | 10 (10.2%) 5.14 (2.51–10.54) | 20 (1.8%) 7.01 (3.86–12.74)  |
| Single twin demise                    | 16 (1.4%)         | 4 (4.1%) 2.8 (0.98–8.41) | 16 (1.4%) 1.75 (0.59–5.18) |
| Both twins demised                    | 6 (0.5%)          | 6 (6.1%) 11.47 (3.77–34.89) | 4 (0.4%) 16 (10%) |
| Losses of normal twins*               | 22 (2.0%)         | 3 (4.5%) 2.3 (0.71–7.56) | 20 (1.8%) 1.93 (0.59–6.38) |

*Losses of normal twins comprise genetically and structurally normal twins. Losses in this group are shown as a percentage of all genetically and structurally normal twins.

bZero cell correction applied for analysis.11

5 | MONOCHORIONIC DIAMNIOTIC TWINS (MCDA)

In the CVS control group, 2.0% (22/1124) of foetuses died before 24+0 weeks, comprising 0.5% (6/1124) as twin pairs and 1.4% (16/1124) single foetal deaths. In the amniocentesis control group, 1.8% (20/1122) of foetuses died before 24 + 0, comprising 0.4% (4/1122) within twin pairs and 1.4% (16/1122) single foetal deaths (Table 2b).
Seven foetuses demised within 2 weeks of CVS including, three twin pairs and one foetus that was survived by their co-twin (Table S2a).

Overall, there were three losses of structurally and genetically normal foetuses, none of which occurred within 2 weeks of CVS (Table S2a). More losses of normal foetuses were observed in the CVS group compared to controls, but with wide confidence intervals crossing the null value due to small overall numbers (4.5% 3/66 vs. 22/1124 RR 2.3 95% CI 0.71–7.56) (Table 2b).

5.2 Amniocentesis

In 65% (52/80) MCDA amniocentesis, both amniotic sacs were sampled, and in 96.2% (50/52), separate needle insertions were used. Two cases required a second attempt to obtain the sample.

Following amniocentesis, there was a significant increase in total foetal deaths prior to 24+0 weeks (12.5%, 20/160, RR 6.39 95% CI 3.57–11.43) with a significant increase deaths of twin pairs (10%, 16/160, RR 18.73 95% CI 7.44–47.17) (Table 2b).

Fifteen foetuses died within 2 weeks of the procedure, one that was survived by their co-twin and seven twin pairs (Table S2b).

There were three losses of genetically and structurally normal foetuses alongside an affected co-twin, two of which occurred within 2 weeks of amniocentesis (Table S2b).

Losses of normal foetuses were comparable in the amniocentesis and control groups with wide confidence intervals crossing the null value due to small overall numbers (3.4% 3/87 vs. 1.8% 20/1122 RR 1.93 95% CI 0.59–6.38) (Table 2b).

6 DISCUSSION

6.1 Main findings

This retrospective cohort study demonstrates that spontaneous losses of twins prior to 24 weeks are increased after CVS and amniocentesis for both DCDA and MCDA pregnancies compared to controls. Whilst losses of structurally and genetically normal twins appear comparable to control groups, the confidence intervals are very wide, and therefore, the data must be interpreted cautiously. Our data are compatible with no difference in risk of normal twin demise between cases and controls, but also with clinically significant differences in both directions. Whilst a clinically important increase in risk cannot be ruled out, there is a possibility that the risk is actually decreased for those undergoing prenatal diagnosis.

6.2 Strengths and limitations

Our multicentre retrospective cohort study includes a relatively large number of DCDA and MCDA twin pregnancies and reflects the provision of contemporary specialised prenatal diagnosis for complicated twin pregnancies with advances in ultrasound technology and invasive techniques. Strict exclusion criteria were applied to ensure that twin subpopulations with higher intrinsic risks of foetal loss did not impact overall outcomes, including MCMA pregnancies, and those affected by TRAP and TTTS. Importantly, we have reported outcomes by chorionicity, described procedural factors, and provided detailed relevant foetal information for all post-procedure demises (Supplemental Tables S1 and S2).

An important limitation of our dataset is considerable demographic data loss due to under-reporting of gestational age, ethnicity, and parity, which is a limitation in describing a priori risk of loss. This was largely due to the inclusion of tertiary referral cases and changes in patient information systems during the study period. Despite efforts made to follow-up outcome data from referring units, some data were not recoverable. It is possible that further adverse outcomes were contained within these missing data. Missing data were more prevalent for DCDA pregnancies as they were more likely to be discharged back to local care. It has recently been shown that although parity does not influence foetal loss, higher maternal weight and black racial origin do contribute to increase the risk.

Our strict exclusion criteria led to relatively small numbers of eligible cases. Changes to patient records meant that older cases could not be reliably searched in two centres. Whilst we made every effort to include appropriate control groups, we do not have post-mortem information for all losses in the control groups. Without this information, we cannot exclude the possibility of losses due to undiagnosed TTTS.

Heterogeneity of technique for CVS and variable reporting of techniques for both procedures are potential confounders for our study and others. We collected all available information on techniques and samples (Tables S1a and S1b, S2a and S2b). However, monochorionic CVS may be carried out using a single sampling site or by sampling adjacent to each placental cord insertion to guard against unidentified heterokaryotypic monzygosity. Similar limitations have affected all other published cohorts.

6.3 Interpretation

The best evidence regarding procedure-related risks for CVS and amniocentesis will continue to come from observational data. The accumulated evidence in singleton pregnancies indicates that CVS and amniocentesis pose a reassuringly small additional risk of pregnancy loss. The limiting factors for such estimates in twin pregnancies are relatively low numbers of procedures and very low event rates. Data are especially limited for monochorionic twin pregnancies. A recent systematic review of singletons included 13 times the number of procedures that were included in a similar systematic review in twins. Monzygosity and monochorionicity confer additional risks that mark these twin pregnancies as a distinct population. Our data indicate a similar risk of post-procedure demise for CVS and amniocentesis in MCDA twins; however, these risks are appreciably higher than those...
we observed in DCDA twins (Tables 2a and b). This observation supports our assertion that dichorionic or pooled twin outcomes should not be extrapolated to the monochorionic population for the purposes of evidence-based guidance and patient counselling.

Since the most recent systematic review of procedure-related loss in twin pregnancies, two further observational datasets have been published.5,15 Dechnunthaphat et al. reported post-amniocentesis demises prior to 24 weeks, but did not stratify outcomes by chorionicity.15 Data from eight foetal medicine units in the UK, Spain, Italy, Bulgaria, and Portugal were analysed in two separate papers. Using logistic regression Elger et al. (2021) concluded that losses prior to 24 weeks gestation increased two-fold following CVS, but the procedure itself did not contribute significantly to the risk of foetal loss.3 The authors attributed the increase in foetal losses to maternal and pregnancy factors.3 When, in an attempt to deal with any potential confounding of maternal and pregnancy factors, the same dataset was analysed using propensity score matching, Gil et al. reported a significant (3.5%) increase in the individual risk following CVS for women at the low baseline risk.

6.4 Clinical and research implications

Our findings of increased post-procedure losses following CVS and amniocentesis in both DCDA and MCDA twin pregnancies and possible clinically important risks to normal twins stand in contrast to the conclusions of recent published studies.

It is important to stress that data derived from small studies with significant heterogeneity will always limit precision of summary statistics. Even when data are sufficiently homogeneous for clinically meaningful pooled analysis, lack of statistical significance does not exclude a possibility of clinically important differences. This is particularly relevant when dealing with low event rates causing bias towards statistical non-significance. When the 95% confidence interval includes 1, the ‘logical’ conclusion is that there is no difference in procedure-related loss. It should be noted, however, that our data are compatible not only with an increase in procedure-related loss but also with the possibility of a clinically significant ‘protective’ effect from invasive procedures. Whilst this could be ignored as implausible, it is not inconceivable that women with MCDA twins undergoing prenatal diagnosis may relax after testing and rest from work. They may benefit from enhanced care with expert imaging and increased surveillance. We encourage future authors not to focus solely on the statistical significance, but to interpret the data much more holistically.

7 CONCLUSION

This study indicates increased twin losses prior to 24 weeks following CVS and amniocentesis in MCDA and DCDA twin pregnancies and these findings contrast somewhat with recently published evidence. The uncertain procedure-related risk to structurally and genetically normal twins persists due to low numbers of adverse outcomes in our cohort and other published analyses. Any counselling should highlight different baseline risks between MCDA and DCDA twins and the contribution of maternal and pregnancy factors to outcomes for complex twin pregnancies.

ACKNOWLEDGEMENTS

We are grateful to the patients and staff in all the units that contributed to this study. There was no funding for this study.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

DATA AVAILABILITY STATEMENT

Data available in article supplementary material.

ORCID

Kate Navaratnam https://orcid.org/0000-0003-0888-1650

REFERENCES

1. Beta J, Lesmes-Heredia C, Bedetti C, Akolekar R. Risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review of the literature. Minerva Ginecol. 2018 Apr;70(2):215-219. https://doi.org/10.23736/s0026-4784.17.04178-8

2. Navaratnam K, Alfirevic Z. Trials and tribulations of meta-analyzing procedure-related risks of amniocentesis and chorionic villus sampling. Ultrasound Obstetr Gynecol Off J Int Soc Ultrasound Obstetr Gynecol. 2019 Oct;54(4):437-441. https://doi.org/10.1002/uog.20351

3. Navaratnam K, Alfirevic Z, Obstetricians RCOG. Amniocentesis and chorionic villus sampling. BJOG Int J Obstetr Gynaecol. 2022;129(1):e1-e15. https://doi.org/10.1111/1471-0528.16821

4. Agarwal K, Alfirevic Z. Pregnancy loss after chorionic villus sampling and genetic amniocentesis in twin pregnancies: a systematic review. Ultrasound Obstetr Gynecol Off J Int Soc Ultrasound Obstetr Gynecol. 2012 Aug;40(2):128-134. https://doi.org/10.1002/uog.10152

5. Elger T, Akolekar R, Syngelaki A, et al. Fetal loss after chorionic villus sampling in twin pregnancy. Ultrasound Obstetr Gynecol Off J Int Soc Ultrasound Obstetr Gynecol. 2012 Jul;58(1):48-55. https://doi.org/10.1002/uog.23694

6. Gil MM, Rodriguez-Fernández M, Elger T, et al. Risk of fetal loss after chorionic villus sampling in twin pregnancies derived from propensity score matching analysis. Ultrasound Obstetr Gynecol Off J Int Soc Ultrasurg Obstet Gynecol. 2021 Nov 29.

7. Badr DA, Bevilacqua E, Carlin A, et al. Antenatal management and neonatal outcomes of monochorionic twin pregnancies in a tertiary teaching hospital: a 10-year review. J Obstet Gynaecol. 2021 Nov;41(8):1199-1204. https://doi.org/10.1080/01443615.2020.1854698

8. HRA. Health Research Authority Decision Tools. [cited 01/02/2020]. http://www.hra-decisiontools.org.uk/research/

9. NICE. Twin and Triplet Pregnancy [NG137]. 2019. [cited 20/12/21]. https://www.nice.org.uk/guidance/ng137

10. Khalil A, Rodgers M, Baschat A, et al. ISUOG Practice Guidelines: role of ultrasound in twin pregnancy. Ultrasound Obstetr Gynecol Off J Int Soc Ultrasound Obstetr Gynecol. 2016 Feb;47(2):247-263. https://doi.org/10.1002/uog.15821
11. Deeks JH, Altman DG. Chapter 10: analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions; 2021. Version 62.

12. Ghi T, Sotiriadis A, Calda P, et al. ISUOG Practice Guidelines: invasive procedures for prenatal diagnosis. *Ultrasound Obstetr Gynecol Off J Int Soc Ultrasound Obstetr Gynecol*. 2016 Aug;48(2):256-268. https://doi.org/10.1002/uog.15945

13. Salomon LJ, Sotiriadis A, Wulff CB, Odibo A, Akolekar R. Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis. *Ultrasound Obstetr Gynecol Off J Int Soc Ultrasound Obstetr Gynecol*. 2019 Oct;54(4):442-451. https://doi.org/10.1002/uog.20353

14. Di Mascio D, Khalil A, Rizzo G, et al. Risk of fetal loss following amniocentesis or chorionic villus sampling in twin pregnancy: systematic review and meta-analysis. *Ultrasound Obstetr Gynecol Off J Int Soc Ultrasound Obstetr Gynecol*. 2020 Nov;56(5):647-655. https://doi.org/10.1002/uog.22143

15. Dechnunthapiphat R, Sekararithi R, Tongsong T, et al. Comparisons of pregnancy outcomes between twin pregnancies with and without second-trimester amniocentesis. *Prenat Diagn*. 2020 Sep;40(10):1330-1337. https://doi.org/10.1002/pd.5783

**SUPPORTING INFORMATION**
Additional supporting information can be found online in the Supporting Information section at the end of this article.

---

**How to cite this article:** Navaratnam K, Khairudin D, Chilton R, et al. Foetal loss after chorionic villus sampling and amniocentesis in twin pregnancies: A multicentre retrospective cohort study. *Prenat Diagn*. 2022;42(12):1554-1561. [https://doi.org/10.1002/pd.6237](https://doi.org/10.1002/pd.6237)